Currencies38606
Market Cap$ 2.48T+8.79%
24h Spot Volume$ 53.39B+10.1%
DominanceBTC56.09%-0.91%ETH10.95%+8.28%
ETH Gas0.04 Gwei
Cryptorank
/

Despite Strategy Woes, 12 of 15 MSTR Institutional Holders Added Shares in Q2


Despite Strategy Woes, 12 of 15 MSTR Institutional Holders Added Shares in Q2

Share:

AI Overview

In Q2 2026, 12 of MicroStrategy’s 15 largest institutional holders added to MSTR positions, with combined holdings rising roughly $700 million; Capital International added $346 million to lift its stake to $3.49 billion (9.4%), Vanguard added $147 million, BlackRock $84 million and Goldman Sachs expanded to $555 million. The inflows come as Strategy sold Bitcoin since May to fund STRC dividends and alter its accumulation stance, but continued institutional buying suggests sustained confidence and potential upside for MSTR stock amid pressure on its capital structure and broader crypto exposure.

Bullish

Predictions Markets

See what traders are focused on

View analytics →
Prediction Banner

In Brief

  • Strategy says 12 of 15 top institutional holders raised MSTR stakes in Q2.
  • Combined holdings among those holders climbed by roughly $700 million.
  • The gains came as Strategy sold Bitcoin to fund its dividends.

Strategy says 12 of its 15 largest institutional holders added to their MSTR positions in the second quarter of 2026. The Q2 13F filings show combined holdings among that group climbed by roughly $700 million.

Strategy released the data to show that big investors still trust its stock. The company built its reputation on a “never sell Bitcoin” pledge, and it broke that pledge this year.

MSTR Institutional Holders Keep Buying

Capital International Investors remains the largest holder. It added $346 million, lifting its stake to $3.49 billion, or 9.4% of shares outstanding.

Vanguard’s two largest entities added a combined $147 million. BlackRock Institutional Trust grew its position by $84 million, and Goldman Sachs nearly quadrupled its stake to $555 million.

However, three holders pulled back. Capital Research Global Investors cut $462 million, the largest reduction in the group, and UBS Financial Services trimmed $142 million.

Geode Capital Management made a smaller cut of $5 million. Even so, the net gain across all 15 holders reached roughly $700 million for the quarter.

In contrast, the Q1 additions were larger. In that quarter, an additional holder was added, bringing the number of top 15 institutional shareholders who added shares to 13, and combined holdings rose by $4.6 billion.

A Test of Institutional Confidence

The filings arrive at a sensitive moment for Strategy. Since May, the company has sold Bitcoin in multiple tranches to fund dividends on its STRC preferred shares.

That marks a reversal of the accumulation-only approach that built its reputation. Executives call the sales capital structure optimization, not a retreat from Bitcoin.

Meanwhile, some analysts question whether the flywheel model still works when Bitcoin’s price sags. The debate centers on how much Strategy can rely on Bitcoin sales without eroding investor trust.

Continued institutional buying gives Strategy a counterargument. It suggests that large, long-term holders remain unbothered by the pressure on its capital structure, at least for now.

As a result, analysts still see upside in MSTR stock, even with Bitcoin’s price flat. The next few quarters will show how far Strategy can lean on its Bitcoin reserves before that confidence fades.

Read the article at BeInCrypto
Read the article at BeInCrypto

Predictions Markets

See what traders are focused on

View analytics →
Prediction Banner

Share:

Predictions Markets

See what traders are focused on

View analytics →
Prediction Banner

Share:

Read More

SK Hynix Up 12%, Samsung Up 9%: Why US Bonds Move Korean Chips

SK Hynix Up 12%, Samsung Up 9%: Why US Bonds Move Korean Chips

In Brief SK Hynix jumped 12.3% and Samsung 8.9% as the Kospi rose 6.13%. Falling Tre...
Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?

Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?

In Brief Retatrutide hype is growing after Phase 3 patients lost an average 28.3% of...